Abstract
Tamoxifen is utilized as adjuvant therapy in women diagnosed with breast cancer. In these patients, despite its positive risk/benefit ratio, tamoxifen may cause secondary effects on the endometrium, with increased risk of malignant diseases (1) . So, the first question to be answered is: “Does tamoxifen increase the incidence of endometrial abnormalities?” The literature presents two meta-analysis-studies that have been developed with this objective (2,3) . Both have demonstrated that long-term use of tamoxifen in patients with breast cancer is associated with a higher incidence of uterine diseases: the studies developed by Tabor et al. (2) and Cohen (3) — 48 papers and 106 papers, respectively. The first one has demonstrated 330 women with endometrial cancer, and other 3,483 without can
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
